Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Orthofix Medical ( (OFIX) ) has shared an announcement.
On April 16, 2026, the U.S. Food and Drug Administration reclassified non-invasive bone growth stimulators from Class III to Class II devices, prompting the Centers for Medicare & Medicaid Services to update billing rules and the Medicare fee schedule for key HCPCS codes effective May 18, 2026. Orthofix Medical now expects average Medicare reimbursement for these products to fall about 10%, has cut its 2026 outlook to net sales of $838 million to $848 million and non-GAAP adjusted EBITDA of $90 million to $93 million, does not anticipate positive free cash flow for the year, and has withdrawn its three-year financial targets while it assesses the longer-term impact of CMS actions.
The reduced Medicare reimbursement is likely to pressure Orthofix’s margins and cash generation in 2026, underscoring the company’s exposure to U.S. public payor policy changes and adding uncertainty for investors and other stakeholders. Management’s decision to deem its prior three-year targets no longer applicable highlights the strategic and financial recalibration the company faces as it navigates evolving reimbursement dynamics in the bone growth stimulation market.
The most recent analyst rating on (OFIX) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Orthofix Medical stock, see the OFIX Stock Forecast page.
Spark’s Take on OFIX Stock
According to Spark, TipRanks’ AI Analyst, OFIX is a Neutral.
The score is held back mainly by ongoing losses and only marginal free-cash-flow generation (despite strong revenue and healthy gross margins), and by weak technical momentum with the stock below key moving averages. These are partially offset by a constructive earnings-call outlook—reaffirmed 2026 guidance, expected margin expansion, and a path to positive free cash flow (excluding potential legal settlements).
To see Spark’s full report on OFIX stock, click here.
More about Orthofix Medical
Orthofix Medical Inc. is a medical device company specializing in non-invasive bone growth stimulators used to support bone healing in patients. The company operates in the orthopedic and spine markets, with a significant portion of its revenue tied to U.S. reimbursement frameworks, including Medicare coverage for these stimulation devices.
Average Trading Volume: 300,740
Technical Sentiment Signal: Strong Sell
Current Market Cap: $491.1M
Find detailed analytics on OFIX stock on TipRanks’ Stock Analysis page.